ClinicalTrials.gg
CompletedNCT04481750Updated Jul 16, 2026Results posted

Study of Oral Edaravone in Healthy Adult Males

A Phase 1 interventional study of MT-1186 and MT-1186-matching placebo in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Shionogi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Mar 2018, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

To evaluate the pharmacokinetics safety, and tolerability of single and multiple doses of edaravone solution and suspension in healthy adult males

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Additional screening criteria check may apply for qualification:

  • Healthy adult male volunteers
  • Japanese or Caucasian
  • Subjects aged between 20 and 45 years at the time of
  • Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

  • Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
  • (BMI) of \<18.0 or >30.0, or body weight of \<50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place)
  • Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs
  • Subjects who do not agree to use an effective method of from initiation of study drug administration to 14 days after completion (discontinuation) of study drug administration
  • Subjects who have previously received edaravone
  • Subjects who have participated in another clinical study and received a study drug within 12 weeks before providing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S1)

    Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S2)

    Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S3-1)

    Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S3-2)

    Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S4)

    Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S5)

    Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S6)

    Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    A single dose MT-1186 (Part 1, Cohort S7)

    Healthy Caucasian male subjects receive a single dose of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    Multiple doses MT-1186 (Part 2, Cohort M1)

    Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo.

    Drug: MT-1186 · Drug: MT-1186-matching placebo

  • Experimental
    Multiple doses MT-1186 (Part 2, Cohort M2)

    Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo

    Drug: MT-1186 · Drug: MT-1186-matching placebo

Interventions

  • Solution or suspension

    Also known as: Edaravone

  • DrugMT-1186-matching placebo

    Solution or suspension

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs)

    Time frame: Day 1 to 8 in Part 1, up to 12 days in Part 2

  2. Area Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone

    Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of unchanged edaravone.

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  3. Area Under the Concentration Versus Time Curve (AUC) of Sulfate Conjugate

    Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of sulfate conjugate.

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  4. Area Under the Concentration Versus Time Curve (AUC) of Glucuronide Conjugate

    Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of glucuronide conjugate.

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  5. Maximum Plasma Concentration (Cmax) of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  6. Maximum Plasma Concentration (Cmax) of Sulfate Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  7. Maximum Plasma Concentration (Cmax) of Glucuronide Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  8. Part 2: Minimum Plasma Concentration at Steady State (Ctrough, ss)

    Time frame: Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  9. Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  10. Time to Reach Maximum Plasma Concentration (Tmax) of Sulfate Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  11. Time to Reach Maximum Plasma Concentration (Tmax) of Glucuronide Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  12. Terminal Elimination Half-life (t1/2) of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  13. Terminal Elimination Half-life (t1/2) of Sulfate Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  14. Terminal Elimination Half-life (t1/2) of Glucuronide Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  15. Lambda-z of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  16. Lambda-z of Sulfate Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  17. Lambda-z of Glucuronide Conjugate

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  18. Mean Residence Time (MRT) of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  19. Apparent Total Clearance (CL/F) of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

  20. Apparent Distribution Volume at Elimination Phase (Vz/F) and Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone

    Time frame: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Secondary outcomes

  1. Change of Heart Rate (HR) From Baseline

    Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

    Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

  2. Change of PR Interval (PR) From Baseline

    Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

    Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

  3. Change of QTcF Interval (QTcF) From Baseline

    Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

    Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

  4. Change of QRS Duration (QRS) From Baseline

    Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6.

    Time frame: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

07

Results

Posted Aug 2, 2024

Participant flow

Period 1 (Fasted)
Participant flow — Period 1 (Fasted)
MilestoneA Single Dose MT-1186 (Part 1, Cohort S1)A Single Dose MT-1186 (Part 1, Cohort S2)A Single Dose MT-1186 (Part 1, Cohort S3)A Single Dose MT-1186 (Part 1, Cohort S4)A Single Dose MT-1186 (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 (Part 1, Cohort S7)Matching Placebo (a Single Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)
Started666666614666
Completed665666614666
Not completed00100000000
Withdrew: Adverse event00100000000
Period 2 (After Meal)
Participant flow — Period 2 (After Meal)
MilestoneA Single Dose MT-1186 (Part 1, Cohort S1)A Single Dose MT-1186 (Part 1, Cohort S2)A Single Dose MT-1186 (Part 1, Cohort S3)A Single Dose MT-1186 (Part 1, Cohort S4)A Single Dose MT-1186 (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 (Part 1, Cohort S7)Matching Placebo (a Single Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)
Started00500000000
Completed00500000000
Not completed00000000000

Outcome measures

PrimaryNumber of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs)
Time frame:
Day 1 to 8 in Part 1, up to 12 days in Part 2
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs)
ParticipantsA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)
Participants with AEs023001122211
Participants with ADRs000000010000
PrimaryArea Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone

Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of unchanged edaravone.

Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng*h/mL
Area Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone
ng*h/mLA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
AUC from time zero to 24 hour (AUC 0-24): Day 1816 ± 2312242 ± 9116254 ± 12362443 ± 81311319 ± 10539034 ± 2738285 ± 1134935 ± 19801917 ± 3834133 ± 1260
AUC from time zero to 24 hour (AUC 0-24): Day 5, only Part 2————————2189 ± 5164279 ± 1166
PrimaryArea Under the Concentration Versus Time Curve (AUC) of Sulfate Conjugate

Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of sulfate conjugate.

Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng*h/mL
Area Under the Concentration Versus Time Curve (AUC) of Sulfate Conjugate
ng*h/mLA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
AUC from time zero to 24 hour (AUC 0-24): Day 116251 ± 714330004 ± 610345666 ± 1044738244 ± 460267693 ± 1417068126 ± 150676709 ± 217144797 ± 1637426132 ± 408339516 ± 3331
AUC from time zero to 24 hour (AUC 0-24): Day 5, only part 2————————24578 ± 418639102 ± 4208
PrimaryArea Under the Concentration Versus Time Curve (AUC) of Glucuronide Conjugate

Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of glucuronide conjugate.

Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng*h/mL
Area Under the Concentration Versus Time Curve (AUC) of Glucuronide Conjugate
ng*h/mLA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
AUC from time zero to 24 hour (AUC 0-24):Day 12360 ± 6484815 ± 9108146 ± 12757406 ± 136814403 ± 155712499 ± 34571201 ± 4548038 ± 18984806 ± 5097932 ± 1190
AUC from time zero to 24 hour (AUC 0-24): Day 5, only part 2————————4698 ± 4998059 ± 1278
PrimaryMaximum Plasma Concentration (Cmax) of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone
ng/mLA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 1755 ± 3561735 ± 7384933 ± 1268899 ± 4648805 ± 9335426 ± 2496208 ± 1123692 ± 15291953 ± 8383855 ± 1676
Day 5————————2308 ± 9414092 ± 1715
PrimaryMaximum Plasma Concentration (Cmax) of Sulfate Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Sulfate Conjugate
ng/mLA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 15481 ± 23379108 ± 210412190 ± 20877324 ± 74314590 ± 210214080 ± 47872913 ± 87011510 ± 25027318 ± 61210830 ± 2346
Day 5————————7402 ± 95411200 ± 1744
PrimaryMaximum Plasma Concentration (Cmax) of Glucuronide Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Glucuronide Conjugate
ng/mLA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 11313 ± 3782272 ± 2793507 ± 1581893 ± 3585322 ± 9583968 ± 912750 ± 2633361 ± 11832145 ± 3563219 ± 666
Day 5————————2209 ± 1563439 ± 428
PrimaryPart 2: Minimum Plasma Concentration at Steady State (Ctrough, ss)
Time frame:
Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · ng/mL
Part 2: Minimum Plasma Concentration at Steady State (Ctrough, ss)
ng/mLMultiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Unchanged Edaravone2.34 ± 0.303.79 ± 0.80
Sulfate conjugate32.91 ± 9.0149.98 ± 11.22
Glucuronide conjugate2.69 ± 0.305.48 ± 1.90
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 10.3 ± 0.10.4 ± 0.10.4 ± 0.11.4 ± 1.60.6 ± 0.30.8 ± 0.40.4 ± 0.10.6 ± 0.30.4 ± 0.10.4 ± 0.1
Day 5————————0.4 ± 0.10.4 ± 0.1
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Sulfate Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Time to Reach Maximum Plasma Concentration (Tmax) of Sulfate Conjugate
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 10.6 ± 0.20.8 ± 0.31.0 ± 0.01.3 ± 0.51.3 ± 0.31.4 ± 0.40.5 ± 0.30.9 ± 0.40.8 ± 0.30.9 ± 0.2
Day 5————————0.8 ± 0.30.8 ± 0.3
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Glucuronide Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Time to Reach Maximum Plasma Concentration (Tmax) of Glucuronide Conjugate
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 10.5 ± 0.30.6 ± 0.20.6 ± 0.21.2 ± 0.61.0 ± 0.31.1 ± 0.40.5 ± 0.30.9 ± 0.40.7 ± 0.30.6 ± 0.2
Day 5————————0.6 ± 0.20.7 ± 0.3
PrimaryTerminal Elimination Half-life (t1/2) of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 13.2 ± 0.95.1 ± 1.59.1 ± 2.45.2 ± 1.711.8 ± 4.9.1 ± 3.32.4 ± 0.76.5 ± 1.74.6 ± 0.44.2 ± 0.2
Day 5————————8.7 ± 3.212.4 ± 1.9
PrimaryTerminal Elimination Half-life (t1/2) of Sulfate Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2) of Sulfate Conjugate
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 17.9 ± 2.67.3 ± 2.65.9 ± 1.75.1 ± 1.36.0 ± 1.64.9 ± 0.35.2 ± 0.66.4 ± 2.63.7 ± 0.23.4 ± 0.3
Day 5————————6.2 ± 0.46.8 ± 1.0
PrimaryTerminal Elimination Half-life (t1/2) of Glucuronide Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2) of Glucuronide Conjugate
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 13.4 ± 1.13.2 ± 0.94.3 ± 0.73.8 ± 0.95.9 ± 1.44.8 ± 0.52.8 ± 0.94.7 ± 1.23.5 ± 0.23.2 ± 0.4
Day 5————————3.9 ± 0.35.2 ± 2.0
PrimaryLambda-z of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · 1/h
Lambda-z of Unchanged Edaravone
1/hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 10.23 ± 0.050.14 ± 0.030.08 ± 0.020.14 ± 0.040.07 ± 0.020.08 ± 0.020.31 ± 0.110.11 ± 0.030.15 ± 0.010.17 ± 0.01
Day 5————————0.09 ± 0.030.06 ± 0.01
PrimaryLambda-z of Sulfate Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · 1/h
Lambda-z of Sulfate Conjugate
1/hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 10.10 ± 0.030.11 ± 0.040.12 ± 0.020.14 ± 0.030.12 ± 0.030.14 ± 0.010.14 ± 0.020.12 ± 0.030.19 ± 0.010.20 ± 0.02
Day 5————————0.11 ± 0.010.10 ± 0.02
PrimaryLambda-z of Glucuronide Conjugate
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · 1/h
Lambda-z of Glucuronide Conjugate
1/hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 10.23 ± 0.090.23 ± 0.070.17 ± 0.030.19 ± 0.050.12 ± 0.020.15 ± 0.010.27 ± 0.070.16 ± 0.040.20 ± 0.010.22 ± 0.03
Day 5————————0.18 ± 0.010.15 ± 0.05
PrimaryMean Residence Time (MRT) of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · h
Mean Residence Time (MRT) of Unchanged Edaravone
hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 11.92 ± 0.462.07 ± 0.261.98 ± 0.153.41 ± 0.622.14 ± 0.202.42 ± 0.452.02 ± 0.202.02 ± 0.321.94 ± 0.151.90 ± 0.26
Day 5————————2.17 ± 0.242.28 ± 0.37
PrimaryApparent Total Clearance (CL/F) of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · L/h
Apparent Total Clearance (CL/F) of Unchanged Edaravone
L/hA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Day 179.77 ± 26.2160.29 ± 22.9032.73 ± 6.4287.07 ± 22.9626.42 ± 2.3036.11 ± 13.62119.41 ± 43.6446.72 ± 20.2764.51 ± 11.6453.40 ± 20.46
Day 5————————57.64 ± 14.5450.74 ± 18.08
PrimaryApparent Distribution Volume at Elimination Phase (Vz/F) and Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
Time frame:
Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5
Reported as:
Mean · L
Apparent Distribution Volume at Elimination Phase (Vz/F) and Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
LA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1)A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)
Vz/F (Part 1), Vss/F (Part 2): Day1348.98 ± 87.82422.67 ± 126.97426.49 ± 130.84620.73 ± 139.24457.99 ± 188.01457.37 ± 175.69384.51 ± 96.92408.95 ± 121.29126.41 ± 29.65105.90 ± 57.04
Vss/F (only Part 2): Day 5————————125.94 ± 40.36121.32 ± 66.83
SecondaryChange of Heart Rate (HR) From Baseline

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

Time frame:
0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Reported as:
Least squares mean · bpm
Change of Heart Rate (HR) From Baseline
bpmA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)Matching Placebo (a Sngle Dose Cohorts
0.25h1.8 ± 0.91-1.2 ± 0.911.8 ± 0.96-0.2 ± 0.92
0.5h-0.2 ± 1.010.2 ± 1.011.3 ± 1.061.2 ± 1.02
1h-0.1 ± 1.28-1.7 ± 1.280.2 ± 1.34-0.2 ± 1.29
1.5h-1.2 ± 1.00-0.3 ± 1.000.2 ± 1.04-0.1 ± 1.01
2h-0.1 ± 0.950.4 ± 0.950.9 ± 0.99-0.1 ± 0.96
4h-0.7 ± 1.36-1.6 ± 1.36-0.1 ± 1.42-1.5 ± 1.37
6h3.2 ± 1.886.4 ± 1.873.8 ± 1.963.8 ± 1.89
8h4.4 ± 1.724.1 ± 1.726.2 ± 1.803.4 ± 1.74
12h1.9 ± 2.0710.1 ± 2.077.6 ± 2.164.6 ± 2.09
24h1.3 ± 1.541.7 ± 1.542.2 ± 1.61-1 ± 1.55
36h8.1 ± 3.079.9 ± 3.0613.2 ± 3.215.7 ± 3.10
48h4.3 ± 2.518.2 ± 2.518.4 ± 2.622.4 ± 2.53
SecondaryChange of PR Interval (PR) From Baseline

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

Time frame:
0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Reported as:
Least squares mean · msec
Change of PR Interval (PR) From Baseline
msecA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)Matching Placebo (a Sngle Dose Cohorts
0.25h-6.8 ± 1.91-3.3 ± 1.99-5.7 ± 1.92-4.5 ± 2.06
0.5h-4.2 ± 1.350.1 ± 1.40-2.4 ± 1.36-3.4 ± 1.45
1h-4.2 ± 1.682.1 ± 1.74-4.0 ± 1.68-4.7 ± 1.80
1.5h-5.2 ± 2.230.0 ± 2.31-4.8 ± 2.24-5.3 ± 2.40
2h-5.9 ± 1.90-0.8 ± 1.97-4.5 ± 1.91-5.9 ± 2.05
4h-3.0 ± 2.64-3.0 ± 2.74-5.3 ± 2.66-5.4 ± 2.85
6h-5.5 ± 1.91-9.6 ± 1.98-6.3 ± 1.92-6.6 ± 2.06
8h-11.6 ± 2.60-9.0 ± 2.70-9.9 ± 2.62-11.9 ± 2.80
12h-6.6 ± 3.91-12.0 ± 4.06-9.0 ± 3.93-11.8 ± 4.21
24h-2.1 ± 2.62-1.6 ± 2.72-8.9 ± 2.63-1.1 ± 2.82
36h-5.7 ± 3.77-6.8 ± 3.91-6.2 ± 3.78-9.5 ± 4.06
48h-3.3 ± 2.630.6 ± 2.73-3.2 ± 2.64-5.4 ± 2.83
SecondaryChange of QTcF Interval (QTcF) From Baseline

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

Time frame:
0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Reported as:
Least squares mean · msec
Change of QTcF Interval (QTcF) From Baseline
msecA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)Matching Placebo (a Sngle Dose Cohorts
0.25h2.0 ± 1.600.7 ± 1.601.6 ± 1.630.8 ± 1.71
0.5h-2.2 ± 1.321.1 ± 1.31-3.8 ± 1.34-4.9 ± 1.41
1h0.3 ± 2.02-0.1 ± 2.02-4.7 ± 2.060.5 ± 2.17
1.5h-5.2 ± 2.232.7 ± 1.68-1.9 ± 1.71-5.3 ± 2.40
2h1.2 ± 1.681.5 ± 2.34-5.1 ± 2.390.8 ± 1.80
4h2.3 ± 2.85-0.9 ± 2.851.4 ± 2.900.7 ± 3.06
6h-5.7 ± 2.96-2.9 ± 2.96-7.6 ± 3.01-2.4 ± 3.18
8h-5.3 ± 2.62-2.9 ± 2.62-7.0 ± 2.66-6.9 ± 2.81
12h-2.3 ± 2.42-4.0 ± 2.42-3.1 ± 2.47-3.3 ± 2.6
24h2.0 ± 2.42-1.2 ± 2.42-5.7 ± 2.46-3.1 ± 2.60
36h-3.0 ± 2.96-5.0 ± 2.96-5.1 ± 3.01-1.4 ± 3.18
48h-1.0 ± 3.22-1.5 ± 3.22-4.4 ± 3.28-0.1 ± 3.46
SecondaryChange of QRS Duration (QRS) From Baseline

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6.

Time frame:
0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.
Reported as:
Least squares mean · msec
Change of QRS Duration (QRS) From Baseline
msecA Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5)A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6)Matching Placebo (a Sngle Dose Cohorts
0.25h-0.7 ± 0.85-0.4 ± 0.840.4 ± 0.87-2.0 ± 0.88
0.5h-0.3 ± 0.77-0.8 ± 0.77-0.5 ± 0.80-1.6 ± 0.80
1h-0.3 ± 0.70-1.5 ± 0.690.5 ± 0.72-1.4 ± 0.72
1.5h-0.4 ± 0.70-0.7 ± 0.800.4 ± 0.83-1.4 ± 0.72
2h-1.5 ± 0.98-0.5 ± 0.980.2 ± 1.01-2.7 ± 1.02
4h-0.5 ± 1.36-2.1 ± 1.36-0.4 ± 1.41-0.5 ± 1.42
6h-0.3 ± 1.311.1 ± 1.31-0.8 ± 1.360.7 ± 1.37
8h-1.2 ± 1.500.0 ± 1.50-2.4 ± 1.55-1.3 ± 1.57
12h0.4 ± 1.71-2.1 ± 1.71-2.0 ± 1.770.0 ± 1.78
24h-0.9 ± 1.26-2.2 ± 1.25-1.4 ± 1.30-1.2 ± 1.31
36h-0.2 ± 1.76-1.5 ± 1.75-2.4 ± 1.810.4 ± 1.83
48h-1.7 ± 1.18-1.5 ± 1.17-1.4 ± 1.22-0.1 ± 1.23

Adverse events

Collected over 8 days in part 1, 12 days in part 2. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A Single Dose MT-1186 (Part 1, Cohort S1)0/6 (0%)0/6 (0%)0/6 (0%)
A Single Dose MT-1186 (Part 1, Cohort S2)0/6 (0%)0/6 (0%)2/6 (33.3%)
A Single Dose MT-1186 (Part 1, Cohort S3)0/6 (0%)0/6 (0%)3/6 (50%)
A Single Dose MT-1186 (Part 1, Cohort S4)0/6 (0%)0/6 (0%)0/6 (0%)
A Single Dose MT-1186 (Part 1, Cohort S5)0/6 (0%)0/6 (0%)1/6 (16.7%)
A Single Dose MT-1186 (Part 1, Cohort S6)0/6 (0%)0/6 (0%)1/6 (16.7%)
A Single Dose MT-1186 (Part 1, Cohort S7)0/6 (0%)0/6 (0%)2/6 (33.3%)
Matching Placebo (a Single Dose Cohorts)0/14 (0%)0/14 (0%)2/14 (14.3%)
Multiple Doses MT-1186 (Part 2, Cohort M1)0/6 (0%)0/6 (0%)2/6 (33.3%)
Multiple Doses MT-1186 (Part 2, Cohort M2)0/6 (0%)0/6 (0%)1/6 (16.7%)
Matching Placebo (Multiple Doses Cohorts)0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventA Single Dose MT-1186 (Part 1, Cohort S1)A Single Dose MT-1186 (Part 1, Cohort S2)A Single Dose MT-1186 (Part 1, Cohort S3)A Single Dose MT-1186 (Part 1, Cohort S4)A Single Dose MT-1186 (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 (Part 1, Cohort S7)Matching Placebo (a Single Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)
HeadacheNervous system disorders0/60/60/60/60/60/62/60/140/61/60/6
ConjunctivitisInfections and infestations0/60/61/60/60/60/60/60/140/60/60/6
NasopharyngitisInfections and infestations0/60/60/60/60/61/60/60/140/60/60/6
Dizziness posturalNervous system disorders0/60/60/60/60/60/60/60/141/60/60/6
PresyncopeNervous system disorders0/60/60/60/60/60/61/60/140/60/60/6
PyrexiaGeneral disorders0/60/61/60/60/60/60/60/140/60/60/6
EnterocolitisGastrointestinal disorders0/60/60/60/60/60/60/60/141/60/60/6
Hepatic function abnormalHepatobiliary disorders0/60/60/60/60/60/60/60/141/60/60/6
Rash pruriticSkin and subcutaneous tissue disorders0/60/60/60/60/60/60/60/140/60/61/6
Blood creatine phosphokinase increasedInvestigations0/60/61/60/60/60/60/60/140/61/60/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)A Single Dose MT-1186 (Part 1, Cohort S1)A Single Dose MT-1186 (Part 1, Cohort S2)A Single Dose MT-1186 (Part 1, Cohort S3)A Single Dose MT-1186 (Part 1, Cohort S4)A Single Dose MT-1186 (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 (Part 1, Cohort S7)Matching Placebo (a Single Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)Total
<=18 years000000000000
Between 18 and 65 years66666661466674
>=65 years000000000000
Sex: Female, Male
Sex: Female, Male(Participants)A Single Dose MT-1186 (Part 1, Cohort S1)A Single Dose MT-1186 (Part 1, Cohort S2)A Single Dose MT-1186 (Part 1, Cohort S3)A Single Dose MT-1186 (Part 1, Cohort S4)A Single Dose MT-1186 (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 (Part 1, Cohort S7)Matching Placebo (a Single Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)Total
Female000000000000
Male66666661466674
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)A Single Dose MT-1186 (Part 1, Cohort S1)A Single Dose MT-1186 (Part 1, Cohort S2)A Single Dose MT-1186 (Part 1, Cohort S3)A Single Dose MT-1186 (Part 1, Cohort S4)A Single Dose MT-1186 (Part 1, Cohort S5)A Single Dose MT-1186 (Part 1, Cohort S6)A Single Dose MT-1186 (Part 1, Cohort S7)Matching Placebo (a Single Dose Cohorts)Multiple Doses MT-1186 (Part 2, Cohort M1)Multiple Doses MT-1186 (Part 2, Cohort M2)Matching Placebo (Multiple Doses Cohorts)Total
White000000620008
Asian (Japanese)66666601266666
08

Study locations

1 site
  • Investigational Site
    Osaka, Japan
09

References and documents

Publications

  • Shimizu H, Nishimura Y, Shiide Y, Matsuda H, Akimoto M, Matsuda M, Nakamaru Y, Kato Y, Kondo K. Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1174-1187. doi: 10.1002/cpdd.925. Epub 2021 Mar 11. PubMed 33704925 ↗
  • Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Matsuda H, Kato Y, Hirai M. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clin Ther. 2022 Dec;44(12):1552-1565. doi: 10.1016/j.clinthera.2022.10.001. Epub 2022 Nov 12. PubMed 36376130 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Aug 2018, 4 months.

Results were first posted in Aug 2024, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 22, 2020
StartActual
Mar 20, 2018
Primary completionActual
Aug 3, 2018
CompletionActual
Aug 3, 2018
Results first posted
Aug 2, 2024
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04481750
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Mar 20, 2018
Primary completion
Aug 3, 2018
Completion
Aug 3, 2018
Results posted
Aug 2, 2024
Last update
Jul 16, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion